BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

BRAFV600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAFV600E mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Endokrynol Pol

Title: Endokrynologia Polska

Publisher: VM Media SP. zo.o VM Group SK

ISSN (Electronic): 2299-8306

ISSN (Print): 0423-104X

Publication date (Electronic): 2019

Volume: 70

Issue: 5

Affiliations

[1 ] Endocrinology and Metabolism Section, Haydarpaşa Education and Training Hospital, Istanbul, Turkey. ozserhat1981@gmail.com.

[2 ] Department of Molecular Biology & Genetics, Arts and Sciences Faculty, Namık Kemal University, Tekirdağ, Turkey.

[3 ] Department of Pathology, Kartal Dr. Lütfi Kırdar Education and Training Hospital, Istanbul, Turkey.

[4 ] Department of Medical Oncology, Kartal Dr. Lütfi Kırdar Education and Training Hospital, Istanbul, Turkey.

[5 ] Endocrinology and Metabolism Section, Haydarpaşa Education and Training Hospital, Istanbul, Turkey.

[6 ] Department of Endocrinology and Metabolism, Marmara University, School of Medicine, Istanbul, Turkey.

Article

Publisher Item ID: VM/OJS/J/62526

DOI: 10.5603/EP.a2019.0025

PubMed ID: 31135058

SO-VID: b420632a-7420-48a2-bdc3-944d2880ab67

History

Keywords: BRAF V600E,papillary thyroid cancer,iodine

Data availability:

Keywords: BRAF V600E, papillary thyroid cancer, iodine

Comments

Comment on this article

scite_

Cited by 6

See all cited by